Dr. Dinesh M. Raj

M.D., D.M. (Cardiology),

Director & Chief Cardiology,

Plexus Med Care, Gujarat.

Heart failure (HF) is a major cause of cardiovascular morbidity and mortality, with preserved ejection fraction (HFpEF) accounting for half of all cases. Patients with HFpEF are typically older, female, and have chronic kidney disease (CKD), a risk factor for mortality. SGLT2i, a drug class that has shown improvements in mortality in HFrEF, has been found to reduce cardiovascular morbidity and mortality in HFpEF patients. The study supports the use of SGLT2i in HFpEF patients with high hypertension, CKD, and black race, suggesting that improvements in mortality may be due to preserving kidney function.

Reference:

John Wiley & Sons,Inc.